Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul:89:102349.
doi: 10.1016/j.bpobgyn.2023.102349. Epub 2023 May 18.

Evaluation of costs associated with fertility treatment leading to a live birth after one fresh transfer: A global perspective

R Matorras  1 , V S Chaudhari  2 , C Roeder  3 , J E Schwarze  4 , K Bühler  5 , K Hwang  6 , C Chang-Woo  7 , S Iniesta  8 , T D'Hooghe  9 , R Mathur  10
Affiliations
Free article
Review

Evaluation of costs associated with fertility treatment leading to a live birth after one fresh transfer: A global perspective

R Matorras et al. Best Pract Res Clin Obstet Gynaecol. 2023 Jul.
Free article

Abstract

Considerable costs are associated with infertility treatment, but little evidence is available on the main drivers of treatment costs. This cost analysis investigated key costs for treatment with assisted reproductive technology (ART) and the proportion of costs attributed to the acquisition of recombinant human follicle-stimulating hormone (r-hFSH) alfa originator for one fresh embryo transfer (ET) leading to a live birth in Spain, Norway, the UK, Germany, Denmark, South Korea, Australia, and New Zealand. The total costs for one ART cycle with a fresh ET leading to a live birth varied between countries (€4108-€12,314). Costs for pregnancy and live birth were the major contributors in European countries, and the costs of oocyte retrieval, monitoring during ovarian stimulation, pregnancy, and live birth were the top contributors in the Asia-Pacific countries, included in this analysis. Acquisition costs for r-hFSH alfa originator contributed to only 5%-17% of the total costs of one ART cycle with one fresh ET leading to a live birth.

Keywords: Assisted reproductive technology (ART); Drug acquisition cost; Live birth; Real-world data; Recombinant human follicle-stimulating hormone (r-hFSH).

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest RM has received lecture fees and grants from Merck and Ferring; support for attending scientific conferences from Gedeon Richter, Hungary, Merck Healthcare KGaA, Darmstadt, Germany, Angelini, Italy, and Ferring, Switzerland. KFB has received honoraria or consultation fees from Merck Healthcare KGaA, Darmstadt, Germany, Ferring, Switzerland, Bayer, Germany, Stiftung Endometriose Forschung, Germany, and Takeda, Japan and is a member of an advisory board for Merck Healthcare KGaA, Darmstadt, Germany. HK and C-WC declare no relevant conflicts of interest. SI has received personal fees and non-financial support from Merck Healthcare KGaA, Darmstadt, Germany, Ferring, Switzerland, and Gedeon-Richter, Hungary. VC, JES, and TDH are employees of Merck Healthcare KGaA, Darmstadt Germany. CR is an employee of Pharma Value Consulting, Switzerland, and at the time of the study was a consultant for Merck, KGaA Darmstadt, Germany. RM has received a lecture fee from Merck Healthcare KGaA, Darmstadt, Germany; support for attending scientific conferences from Gedeon Richter, Hungary, and Merck Healthcare KGaA, Darmstadt, Germany; and is the Chair of the British Fertility Society.

Similar articles

See all similar articles

Cited by

Substances

LinkOut - more resources